A new approach to treating epilepsy, focusing on the underlying causes of the neurological disorder rather than just managing symptoms, is showing early promise. Researchers at the Hebrew University of Jerusalem have developed an experimental peptide, TXM-CB3, that aims to reduce brain inflammation and oxidative stress – factors increasingly linked to epilepsy’s progression and drug resistance, which affects roughly 40% of patients[[3]]. The findings,published in *Redox Biology*,suggest a potential for therapies that could alter the course of the disease,notably wiht early intervention.
A new experimental treatment developed at the Hebrew University of Jerusalem shows promise in reducing the frequency of epileptic seizures and mitigating associated neurological damage. The approach, which targets oxidative stress and inflammation in the brain, differs from current medications that primarily focus on suppressing seizure symptoms, suggesting a potential to modify the course of the disease – particularly with early intervention.
Researchers at the Hebrew University of Jerusalem are exploring a novel approach to epilepsy treatment, shifting the focus from managing seizures to addressing the underlying biological processes that contribute to the condition’s recurrence and progression. The team has developed an experimental compound, a synthetic peptide called TXM-CB3, designed to mimic the action of a naturally occurring protein in the body called thioredoxin.
Thioredoxin is a key component of the body’s internal defense system, helping to manage oxidative stress and regulate inflammatory processes. Scientists are increasingly linking these two mechanisms to both the triggering of epileptic seizures and the long-term development of the disease, even in cases where current therapies are ineffective. “Most epilepsy treatments focus on reducing seizures, but our goal was to see if we could influence the underlying processes that drive the disease forward,” explained Professor Tawfeeq Shekh-Ahmad, of the Faculty of Medicine, who led the research.
The study, published in the journal Redox Biology, was primarily conducted by doctoral students Prince Kumar Singh and Shweta Maurya, with collaboration from Professor Daphne Atlas of the Institute of Life Sciences, who designed the family of peptides to which TXM-CB3 belongs. The researchers began by testing the compound on cell models that mimic seizure activity, where it successfully reduced markers of oxidative damage and modulated the immune response to a less inflammatory profile.
Next, they tested TXM-CB3 in preclinical models of drug-resistant epilepsy, characterized by recurring seizures. They evaluated two key scenarios. In the first, administering the peptide immediately following an event similar to status epilepticus – a prolonged seizure – delayed the onset of subsequent seizures, reduced their frequency, and improved the preservation of brain structures associated with memory. Animals treated early also exhibited fewer indicators of anxiety and performed better on short-term memory tests.
When treatment was initiated later, after a cycle of recurring seizures had already been established, the peptide still demonstrated the ability to reduce seizure activity over time. However, researchers noted that memory deficits that had already developed did not show substantial improvement. This difference in outcomes depending on the timing of intervention underscores, according to the team, the critical importance of early therapeutic intervention. “The fact that we observed both a reduction in seizure activity and signs of brain protection in these experimental models strengthens the hypothesis of developing treatments that harness the body’s own protective pathways,” commented Professor Daphne Atlas.
Epilepsy affects approximately 50 million people worldwide, according to the World Health Organization, and up to 40% of cases are resistant to existing drugs. These medications largely work to control seizures as they occur, without significantly altering the long-term course of the disease. The strategy being explored here is different: it aims to calm the chemical and immune signals that may underlie the chronic nature and progression of the condition. This research offers a potential new avenue for treatment in a population where current options are limited.
It’s important to note that this research is still in its early stages. While the results are promising, they come from experimental models, and extensive further study is needed to evaluate safety, dosage, and efficacy in humans. Despite this, the investigation points toward a tangible direction for the future, suggesting the possibility of offering individuals with epilepsy not only better seizure control but also a therapy that could mitigate long-term neurological consequences and improve quality of life. The brain, researchers suggest, possesses its own resilience mechanisms, and science is now attempting to enhance them.
Referência bibliográfica:
Singh, P. K., Maurya, S., Atlas, D., & Shekh-Ahmad, T. (2026). TXM-CB3, a thioredoxin-mimetic peptide, shows promise in slowing epilepsy progression. Redox Biology, [70], 103121. https://www.sciencedirect.com/science/article/pii/S2213231726000194
NR/HN/AlphaGalileo
Outros artigos com interesse:
